pathogenesis Flashcards
scleredema: Px
↑collagen/mucin( increased synthesis-insulin/hypoxia/vascular damage, reduced degradation-collagenase) 1- post strep 2- monoclonal gammopathy, 3- diabeticorum(IDDM) irreversibly glycosylated collagen
scleromxydema Px
Px:mucin,Fibroblast proliferation;
- IgGlamda monoclonal gammopathy/plasma cell dyscrasia 2. circulating human factors
- absence thyroid disease
aGVHD: Px
1.HSCT, host APC activated 2. donor T cell proliferation(cytotoxic T/NK cells) 3. target tissue destruction(skin liver GIT)
cGVHD:Px
1.autoAb, sclerotic 2. BAFF(rituximab)
LSA
LSA: HLA DR1*12 , autoimmune(thyroid) ECM1, oxidative stress, infectious?borrelia, 8% SCC
EI
type4 CMI to Ag stimuli( infx-TB(
HV-
EBV, NKT lymphoma/hemophagocytosis; PMLE: persistent DTH response against photoinduced altered endogenous Ag; PCT:
actinic prurigo
-persistent PMLE variant, HLADR4, thalidomide anti TNFa, UVR
CAD -
1.UVB+UVA absorption by DNA/RNA; 2,DTH response(endog/photoinduced cutaneous Ag, CD8+ Infiltrate; 3.+photoallergy compositae/sunscreen, HIV(11% local)
phototoxic-
UVR activation , direct cellular injury; exagerrated sunburn,dose-dependent,photodistr telangiectasia(CCB); pseudoporphyria(frusemide, tetracycline, nalidixic acid) NSC: phenothiazine(chlorpromazine, promethazine); resolution time: T1/2 , persistent photoactive molecules(quinine, thiazide 9m)
photoallergy-
drug+photon->photoproduct+protein binding=Ag–>hypersensitivity e.g.
LABD
:LAD 97kDa ectodomain BP180
MMP-autoAb
BP180(BPAG2 C terminal), laminin 332(a3); a6b4(ocular MMP)
EBA
-acquired immune mediated, 290/145 kDa col7(anchoring fibril) autoab, HLADRB1501, response to immunosuppresion; A/W: crohn’s, SLE/RA/thyroiditis
Pvegetans-
drugs(ACEi), malignancy, dsg3
PNP:
BP230, dsg1/3, desmoplakins, envoplakin, periplakin/plectin,tumor Ag- NHL, CLL, castleman waldenstrom, thymoma sarcoma;
PV/PF-
dsg(desmosome) compensation theory blister localisation-expression: dsg1(supf dermis), dsg3(deep epidermis, mucosa); HLA susceptibility
DH:
HLA DQ0501/B102, gluten sensitive enteropathy, IgA anti TG3 Ab, neutrophilic, granular IgA, dapsone improves(anti-neutrophilic),iodide worsen
IgA pemphigus-
IgA desmocollin1 , dsg1/3, dapsone
EM
PGx: HLADQw3/drw53,HSV(REM-70%)/mycoplasma/drug-NSAID/AC/sulfonamide; IBD/Behcets
FDE- pGx:
1) resting lesion: quiescent primed intraepidermal CLA+CD8+ T cell;
2) activated by drug exposure, IFNy/cytotoxic granule release;
3) fully evolved- keratinocyte cytolysis;
4) resolution-Treg recruitment amelioration but memory cells persist
LCV Px
Px:type 3 Immune complex( ab+drug related haptens) post capillary venules, activate complement cascade neutrophil chemotaxis ,profinflammatory cytokine/vasoactive amine
AHEI
PxLCV, IC deposition, Ag trigger( Drug, Infx, Vaccine)
UV PGx
: mast cell degranulation via calcium/energy dependent steps; IgE receptor cell Xlink allergen, histamine granules, leukotrienes
PAN
Px:1.immune complex-mediated DIF IgM/c3; ↑titre antiphosphatidyl PT complex ab/LAC; 2.classical complement pathway( PT bind apoptotic endothelial cells–>Ab)
- local circulatory dysfunction(LL)
infx: GAS(Ag-IC Walls)/hepB(systemic 30%)/c/TB; IBD, minocycline(p ANCA+)
LV
Px: unknown, coagulation dysfunction(local/systemic)–>fibrin thrombi (supf dermal)
EAC PathoGx:
- hypersensitivity infx-dermatophyte, candida , EBV, VZV poxvirus, HIV,
- drugs-piroxicam penicilin, malignancy-lymphoma, 3.leukemia, TNFa IL2 link,
RPC
scratching, keratinocytes- AGE(advanced glycated end)product-receptor interaction, induction terminal ddx, upward migration-TEE,↑fibronectin, TGFb3
EB pruriginosa:
DEB variant AD/AR, COL7A1 mutation-glycine subtitution, rudimentary af
Px ALHE:
reactive>neoplastic, mural damage, trauma, AV shunting
Cutaneous mets-
precocious, synchronous, metachronous
pGx:mechanical-1st capillary bed, regional extension
paget’s seed+soil-microenvironmental, organ-selective,
breast-ectoderm derivation, similar signalling pathway embryogenesis: Wnt, hedegehog,
NLD
11% have DM, 0.3% DM have NLD
unknown, microangiopathic changes, anticollagen Ab
NXG
Px: IgG monoclonal gammopathy, indirect/paraneoplastic effect(monocyte proliferation, lipid proliferation)
RDD
Px: HHV6 related, autoimmune lymphoproliferative syndrome-Fas mediated apoptosis
XD
Px: normolipemic, reactive histiocytosis
xanthoma- ERUPTIVE
primary(see below), secondary( DM/cholestasis/PBC/hypothyroidism)
145 ET(eruptive- hypertriglyceriderma type 1/IV/V, lipoprotein lipase def, familial,
obesity, DM, retinoid),
plane xanthoma
primary(see below), secondary( DM/cholestasis/PBC/hypothyroidism)
Play Bad(planar, dysBetalipoproteinemia) familial Criminals!(homozygous hyperC)
or plain normal(ipemic)-monoclonal gammopathy
tendinous xanthoma
Terms & Conditions(tubero/tendinous, hypercholesterolemia-familial/dysbetalip)
disseminated GA
PX:1. DTH unknown Ag( trauma, insect vite, TB, UVB, viral) 2. Th1-IFNY, macrophage inhibitory factor, elastic tissue injury 3. generalised: HLABw55,DM, HIV, malignancies- lymphoproliferative, solid
OFG
PathoGx: cell mediated hypersensitivity food additives
PNGD/IGD-
immune complex deposition , small vessel vasculitis , collagen degeneration , trauma(extensor)
follicular mucinosis
mucin sebaceous gland/ORS, circulating IC, CMI, S aureus Ag;
EDV-
AR, EVER1/2 Susceptibility locus endoplasmic reticulum genes HPV immunity
SDRIFE
: blactam/iodinated radiocontrast, valacyclovir,type IV DTH, +PT ni, me, drug
CD4+ infiltrate ↑ CD62P
hailey hailey,
AD, ATP2C1, golgi associated Ca2+ ATPase(hSPCA1), intracellular ca signalling,
Reiter’s
Px: seroneg spondyloarthropathy, HLAB27, post GUT(CT) GIT(shigella salmonella yersinia)
angiosarc
malignant endothelial ddx, stewart treves(lymphedema, VEGFR3); post RT(breastCA); MYC/FLT4 gene amplification; env( vinyl chloride, arsenic)
KS
HHV8 infx(SI,saliva, blood, HIV coinfection); transcriptional reprogramming-lymphangigenic molecules also in multicentric castleman disease, 1 effusion lymphoma
Melanoma-
1) BRAF/cKIT-acral mucosal/CDKN2A-p14,16/NRAS mutations,affect cellular signalling pathways,
2) UVA, fitzpatrick1/2,
3) GCMN,>50 dysplastic
BCC:
Px-1.intermmittent UVR 2.genomic stability without precursors, PTCH, p53 3.locally invasive(no mets) stroma Xtalk dependent
Gorlin:
AD PTCH inhibit SHH/SMO/gli/downstream target;
EMPD
PGx: primary-toker cells origin; secondary: cutaneous extension underlying adnexal carcinoma(GCDFP15+, CD 20-)/visceral malignancy- CLR, urothelial, cervical, prostatic, ovarian, endometrial
HIES
AD STAT3, AR DOCK8;
WAS
-XLR WAS: